Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Altered Tacrolimus Formulations
NCT02341274Phase 1Completed
- Sponsor
- Indiana University
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tacrolimus in transplant rejection (4 arms), sponsored by Indiana University. Primary endpoints: Maximum Blood Concentration at 24 hours, Area Under the Curve from 0 to 24 hours and 1 more. Started Nov 2016; status: completed.
02
Drugs
tacrolimus
03
Conditions
transplant rejection
Beyond the preview
Go deeper on NCT02341274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341274.